Cell Bio Human Tech Co. Ltd. (318160) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cell Bio Human Tech Co. Ltd. (318160:KRX), powered by AI.

Current Price
₩6,280
P/E Ratio
6.7
Market Cap
58.6B
Sector
Consumer Defensive
What is the Cell Bio Human Tech Co. Ltd. stock price forecast?

Cell Bio Human Tech Co. Ltd. is currently trading at ₩6,280. View real-time AI analysis on Alpha Lenz.

What is Cell Bio Human Tech Co. Ltd. insider trading activity?

View the latest insider trading data for Cell Bio Human Tech Co. Ltd. on Alpha Lenz.

What is Cell Bio Human Tech Co. Ltd.'s P/E ratio?

Cell Bio Human Tech Co. Ltd.'s P/E ratio is 6.7.

Cell Bio Human Tech Co. Ltd.

KRX · 318160
₩6,280-1,690(-21.20%)Market closedKRX regular session 09:00–15:30 KST
Ask about Cell Bio Human Tech Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Cell Bio Human Tech Co. Ltd. trades at a P/E of 6.7 (undervalued) with strong ROE of 16.9%. 3Y revenue CAGR of 22.8% highlights clear growth momentum.

Ask for details

Company Overview

Cell Bio Human Tech Co. Ltd. is a prominent entity in the biotechnology sector specializing in advanced healthcare and biomedical solutions. The primary function of this company is to innovate and manufacture cutting-edge biopharmaceutical products, focusing on addressing critical health challenges. It operates predominantly in the fields of cell therapy, regenerative medicine, and antibody technology, playing a pivotal role in advancing treatments for complex diseases. A notable feature of Cell Bio Human Tech Co. Ltd. is its emphasis on research and development, which propels the continuous discovery of novel medical interventions. The company's deep-rooted commitment to utilizing cell engineering and genetic technologies underlines its contribution to the advancement of precision medicine. In the financial market, Cell Bio Human Tech Co. Ltd. serves as a crucial player within the biotechnology industry. It reflects trends in biomedical innovation and investment flows in health technology, engaging with stakeholders ranging from healthcare professionals to investors keen on the future of medical treatments. Operating from its base in Asia, the company significantly impacts global health markets by providing solutions that contribute to the well-being of populations worldwide.

CEO이권선
SectorConsumer Defensive
IndustryHousehold & Personal Products
Employees58

Company Statistics

FY 2025

Profile

₩58,639,581,640Market Cap
₩51,066,196,360Revenue
9.34MShares Out
58Employees

Margins

36.90%Gross
22.93%EBITDA
18.25%Operating
17.59%Pre-Tax
17.03%Net

Valuation

6.72P/E
1.03P/B
1.15EV/Sales
5.59EV/EBITDA
-11.02P/FCF

Growth (CAGR)

22.85%Rev 3Yr
12.30%Rev 5Yr
38.13%Op Inc 3Yr
11.98%Op Inc 5Yr
44.37%Net Inc 3Yr
15.58%Net Inc 5Yr

Returns

12.30%ROA
16.91%ROE
13.16%ROIC

Financial Health

₩15,916,988,540Cash & Cash Equivalents
₩13,537,540,030Net Debt
49.92%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cell Bio Human Tech Co. Ltd. (ticker: 318160) is a company listed on KRX in the Consumer Defensive sector (Household & Personal Products). It has approximately 58 employees. Market cap is $58.6B.

The current price is ₩6,280 with a P/E ratio of 6.72x and P/B of 1.03x.

ROE is 16.91% and operating margin is 18.25%. Annual revenue is $51.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cell Bio Human Tech Co. Ltd. (318160) Stock Forecast 2026 ₩6,280 — Price, Financials & Analyst Targets | Alpha Lenz